{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056914","form_type":"8-K","ticker":null,"cik":"0001851194","company_name":"Ventyx Biosciences, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.829544+00:00","generated_at":"2026-06-02T07:04:31.267206+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ventyx Q1 2024 net loss $38.6M; cash $302.6M; Phase 2a trials in H2 2024","bullets":["Net loss of $38.6M in Q1 2024 vs $38.9M in Q1 2023; R&D $33.7M, G&A $8.0M.","Cash, cash equivalents and marketable securities of $302.6M as of March 31, 2024; runway into H2 2026.","Phase 2a trials of CNS-penetrant NLRP3 inhibitor VTX3232 to start H2 2024 in early Parkinson's and obesity with CV risk factors.","Phase 2 topline data for TYK2 inhibitor VTX958 in Crohn's disease expected early H2 2024; enrollment completed.","Positive Phase 2 CAPS data for VTX2735; seeking partner for VTX002 Phase 3 in ulcerative colitis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056914","json":"https://secwatch.observer/filing/0000950170-24-056914.json","markdown":"https://secwatch.observer/filing/0000950170-24-056914.md","text":"https://secwatch.observer/filing/0000950170-24-056914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851194/000095017024056914/0000950170-24-056914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851194/000095017024056914/vtyx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:04:31.267206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"491303f95cdb24a85b613fcaf52edd09e4015b6c","claim":"Ventyx Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"today announced financial results for the first quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851194/000095017024056914/0000950170-24-056914-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}